Stockreport

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Lexicon Pharmaceuticals, Inc.  (LXRX) 
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: lexpharma.com/investors
PDF Strong Interest in Trial Participation Resulted in Enrollment Exceeding Target by 20 Percent and Completion Ahead of Schedule Top-line Data Expected in Q1 2 [Read more]